Financial Report: Pfizer 3Q10

Pfizer 3Q10

3Q Revenues: $16.2 billion (+39%*)

3Q Earnings: $866 million (-70%*)

YTD Revenues: $50.2 billion (+50%*)

YTD Earnings: $5.4 billion (-32%*)

Comments: Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptosar in Europe. U.S. revenues were $7.1 billion (+48%) and International revenues were $9.1 billion (+33%). Primary Care revenue was $5.7 billion (+2%). Specialty Care revenue was $3.7 billion (+136%). Established Products accounted for $2.2 billion (+31%). Emerging Markets revenue was $2.1 billion (+36%). Oncology sales were $335 million (-10%).

* All figures do not include Wyeth revenues or earnings from 2009.